CHILDHOOD MDS TREATED WITH AML REGIMENS

被引：0
|
作者：
HASLE, H
KERNDRUP, G
机构：
来源：
GEMATOLOGIYA I TRANSFUZIOLOGIYA | 1995年 / 40卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [41] Categorizing Molecular Mutations in MDS and AML
    Rose, Dominic
    Haferlach, Torsten
    Kern, Wolfgang
    Haferlach, Claudia
    BLOOD, 2015, 126 (23)
  • [42] What came first: MDS or AML?
    Walter, Matthew J.
    BLOOD, 2015, 125 (09) : 1357 - 1358
  • [43] Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine
    Cluzeau, Thomas
    Mounier, Nicolas
    Karsenti, Jean-Michel
    Richez, Valentine
    Legros, Laurence
    Gastaud, Lauris
    Garnier, Georges
    Re, Daniel
    Montagne, Nathalie
    Gutnecht, Jean
    Fuzibet, Jean Gabriel
    Auberger, Patrick
    Raynaud, Sophie
    Cassuto, Jill-Patrice
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (09) : 780 - 783
  • [44] Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors
    Oran, Betul
    Garcia-Manero, Guillermo
    Saliba, Rima M.
    Alfayez, Mansour
    Al-Atrash, Gheath
    Ciurea, Stefan O.
    Jabbour, Elias J.
    Mehta, Rohtesh S.
    Popat, Uday R.
    Ravandi, Farhad
    Alousi, Amin M.
    Kadia, Tapan M.
    Konopleva, Marina
    DiNardo, Courtney D.
    Rezvani, Katy
    Shpall, Elizabeth J.
    Sharma, Padmanee
    Kantarjian, Hagop M.
    Champlin, Richard E.
    Daver, Naval
    CANCER, 2020, 126 (10) : 2193 - 2205
  • [45] Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens
    Marie Sébert
    Lucie Freiman
    Cendrine Chaffaut
    Agnès Guerci
    Pierre Peterlin
    Sylvain Thépot
    Odile Beyne-Rauzy
    Sophie Park
    Thomas Cluzeau
    Fatiha Chermat
    Pierre Fenaux
    Claude Preudhomme
    Emmanuelle Clappier
    Sylvie Chevret
    Lionel Adès
    Nicolas Duployez
    Matthieu Duchmann
    Leukemia, 2024, 38 : 918 - 922
  • [46] ICSH guidelines on immunophenotyping in AML and MDS
    Kern, W.
    ONKOLOGIE, 2013, 36 : 36 - 37
  • [47] Good General Health In Survivors of Childhood AML Treated with Chemotherapy Only: A NOPHO-AML Study
    Hasle, Henrik
    Glosli, Heidi
    Jahnukainen, Kirsi
    Jarfelt, Marianne
    Jonmundsson, Guomundur
    Malmros-Svennilson, Johan
    Nysom, Karsten
    Molgaard-Hansen, Lene
    BLOOD, 2010, 116 (21) : 470 - 471
  • [48] FLOW CYTOMETRIC EVALUATION OF MDS/AML
    Kern, Wolfgang
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2014, 36 : 20 - 21
  • [49] MOLECULAR BASIS FOR AML, MDS AND MPN
    Kitamura, T.
    Nakahara, F.
    Kato, N.
    Watanabe-Okochi, N.
    Komeno, Y.
    Doki, N.
    Togami, K.
    Uchida, T.
    Kagiyama, Y.
    Inoue, D.
    Enomoto, Y.
    Oki, T.
    Harada, H.
    Chiba, S.
    Kitaura, J.
    EXPERIMENTAL HEMATOLOGY, 2010, 38 (09) : S107 - S108
  • [50] Targeting CBP/β-Catenin in MDS/AML
    Jiang, E.
    Nguyen, C.
    Kim, H. N.
    Khaled, Samer
    McDonald, Tinisha
    Marcucci, Guido
    Teo, J. L.
    Kahn, M.
    Kim, Y. M.
    ANNALS OF HEMATOLOGY, 2019, 98 : S49 - S50
12345